Diagnosis and management of type 2 diabetic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 8, 2017, Pages 1366-1373

  Doshi, Simit M ^a   Friedman, Allon N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR ANTAGONIST; MINERALOCORTICOID; PHOSPHODIESTERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; URINARY TRACT AGENT;

DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HUMAN; MICROALBUMINURIA; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URINALYSIS; WEIGHT REDUCTION; BARIATRIC SURGERY; BLOOD PRESSURE; CALORIC RESTRICTION; CHRONIC KIDNEY FAILURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BARIATRIC SURGERY; BLOOD PRESSURE; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIAGNOSIS, DIFFERENTIAL; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE OF TESTS; RENAL AGENTS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 85025468669     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11111016     Document Type: Review

References (46)

1. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH: Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316: 602–610, 2016
2. Bailey RA, Wang Y, Zhu V, Rupnow MF: Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 7: 415, 2014
3. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME: Diabetic kidney disease: A report from an ADA Consensus Conference. Am J Kidney Dis 64: 510–533, 2014
4. Bakris GL, Molitch M: Microalbuminuria as a risk predictor in diabetes: The continuing saga. Diabetes Care 37: 867–875, 2014
5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225–232, 2003
6. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB: Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: Results from the DEMAND study. Cardiorenal Med 2: 1–10, 2012
7. Kramer HJ, Nguyen QD, Curhan G, Hsu CY: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289: 3273–3277, 2003
8. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group: Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 29: 1802–1809, 2011
9. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC: Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 32: 1497–1502, 2009
10. Chang TI, Park JT, Kim JK, Kim SJ, Oh HJ, Yoo DE, Han SH, Yoo TH, Kang SW: Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease. Diabetes Res Clin Pract 92: 198–204, 2011
11. Pham TT, Sim JJ, Kujubu DA, Liu IL, Kumar VA: Prevalence of nondiabetic renal disease in diabetic patients. Am J Nephrol 27: 322–328, 2007
12. Bermejo S, Soler MJ, Gimeno J, Barrios C, Rodríguez E, Mojal S, Pascual J: Predictive factors for non-diabetic nephropathy in diabetic patients. The utility of renal biopsy. Nefrologia 36: 535– 544, 2016
13. Tone A, Shikata K, Matsuda M, Usui H, Okada S, Ogawa D, Wada J, Makino H: Clinical features of non-diabetic renal diseases in patients with type 2 diabetes. Diabetes Res Clin Pract 69: 237– 242, 2005
14. Sharma SG, Bomback AS, Radhakrishnan J, Herlitz LC, Stokes MB, Markowitz GS, D’Agati VD: The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 8: 1718–1724, 2013
15. KDOQI: KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49[Suppl 2]: S12–S154, 2007
16. Standards of medical care in diabetes-2016: Summary of revisions. Diabetes Care 39[Suppl 1]: S4–S5, 2016
17. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713, 1998
18. Ismail-Beigi F, Craven TE, O’Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U; ACCORD Study Group: Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81: 586–594, 2012
19. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Collaborative Study Group: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170–2179, 2005
20. Ruggenenti P, Fassi A,; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. NEngl J Med 351: 1941–1951, 2004
21. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–878, 2001
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001
23. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Re-noprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001
24. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553, 2008
25. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. NEngl J Med 369: 1892–1903, 2013
26. Palevsky PM, Zhang JH, Seliger SL, Emanuele N, Fried LF; VA NEPHRON-D Study: Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade. Clin J Am Soc Nephrol 11: 1944–1953, 2016
27. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. NEngl J Med 358: 2433–2446, 2008
28. Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D: Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes Endocrinol 4: 309– 317, 2016
29. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998
30. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control andvascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129–139, 2009
31. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S; ADVANCE Collaborative Group: Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83: 517– 523, 2013
32. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group: Effect of intensive treatment of hyper-glycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 376: 419–430, 2010
33. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597, 2014
34. Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjöström CD: Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59: 2036–2039, 2016
35. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334, 2016
36. US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), 2016. Available at: http://www. fda.gov/Drugs/DrugSafety/ucm505860.htm. Accessed February 15, 2017
37. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M: Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36: 3460–3468, 2013
38. Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group: Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care 39: 2304– 2310, 2016
39. Look AHEAD Research Group: Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2: 801–809, 2014
40. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Supp 3: 1–150, 2013. Available at: http://www.kdigo.org/ clinical_practice:guidelines/pdf/CKD/KDIGO_2012_CKD_GL. pdf. Accessed February 15, 2017
41. Friedman AN, Wolfe B: Is bariatric surgery an effective treatment for type II diabetic kidney disease? Clin J Am SocNephrol 11: 528– 535, 2016
42. Chang AR, Chen Y, Still C, Wood GC, Kirchner HL, Lewis M, Kramer H, Hartle JE, Carey D, Appel LJ, Grams ME: Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 90: 164–171, 2016
43. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS: Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143–154, 2007
44. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25: 1083–1093, 2014
45. Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ: Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. Eur J Prev Cardiol 23: 758–768, 2016
46. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–-Diabetic Nephropathy (ARTS-DN) Study Group: Effect of finer-enone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 314: 884–894, 2015